Novartis Purchase Of Chiron Puts Spotlight On Biologics
Drug maker Novartis AG's acquisition of Chiron Corp. will expand the Swiss company's footprints in the U.S. biotech market even as its generics division braces for a battle to launch the...To view the full article, register now.
Already a subscriber? Click here to view full article